Healthcare
Hogy Medical Co.,Ltd.(HGYMF)
Live Price
Offline$34.99
+0.00% today
1Y Change
+43.76%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $143.59B
- Revenue Growth
- +0.1%
- EPS Growth
- -41.2%
- Dividend Yield
- 1.4%
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hogy Medical Co.,Ltd. (HGYMF) is a Healthcare stock with a market cap of $143.59B and listed on OTC. The stock last traded around $34.99 and up 43.8% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +0.1%, EPS growth of -41.2%, a dividend yield of 1.4%. What stands out right now is revenue +0.1%, EPS -41.2%, free cash flow +44.8% with operating margin 6.3% and ROIC 0.5%. The dividend is present but secondary, with a yield around 1.4%. Valuation already assumes a fairly strong business story at P/E 646.8 and price/sales 3.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HGYMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.1% vs +7.6% peer median
Operating Margin
Below sector median
+6.3% vs +19.4% peer median
P/E
Above sector median
646.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +0.1% and EPS is at -41.2%, with operating margin around 6.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.4%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
HGYMF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HGYMF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HGYMF Max Drawdown
-1.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HGYMF and SPY.
Company Overview
Hogy Medical Co.,Ltd.
Other OTC
Hogy Medical Co.,Ltd., together with its subsidiaries, provides medical-use and non-woven fabric, surgical kit, and other products in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, personal protective equipment and wearables, drapes, packaged products, instrument table covers, and wraps; and Tigalyer, a non-woven fabric with liquid barrier properties for waterproofing applications. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stands; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers Opera Master, a surgery management system; ME equipment operation management system; narcotics/poisons box, an automatic drug reading management system using radio frequency identification; endoscope holders; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was incorporated in 1961 and is headquartered in Tokyo, Japan.
- Leadership
- Hideki Kawakubo
- IPO Date
- Dec 2, 2014
- Employees
- 1.4k
- Street Address
- 7-7, Akasaka 2-chome
- Mailing
- Tokyo, 107-8615
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 6229 1300
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 646.8
- EV/EBITDA
- 17.5
- Price/Sales
- 3.8
- Price/Book
- 1.9
Growth
- Revenue
- +0.1%
- EPS
- -41.2%
- Free Cash Flow
- +44.8%
Profitability
- Gross Margin
- 32.3%
- Operating Margin
- 6.3%
- Net Margin
- 0.6%
- ROE
- 0.3%
- ROIC
- 0.5%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 5.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.